Shimmer Launches VeriSense Sensor Platform for Clinical Trials with Access to Raw Physiological and Kinematic Data

VCBeat (WeChat ID: vcbeat) has learned that Shimmer, a medical device company, recently launched VeriSense, a new sensor platform for clinical trials. The platform primarily provides real-time, simple, and effective collection of physiological and kinematic data in the field of clinical trials.

Shimmer is a mature wearable technology services and sensor manufacturing company headquartered in Dublin, Ireland. Since its establishment in 2006, the company has launched a range of wearable devices leveraging advanced wireless sensor technologies. These products not only provide users with high-quality data feedback but also ensure the scientific rigor of data for research purposes.

Geoff Gill, President of Shimmer Americas, stated: “Pharmaceutical companies, regulatory agencies, and patients are increasingly recognizing the role of real-time data in health and quality of life. They are calling for the launch of new monitoring platforms on the market, particularly for chronic diseases, to objectively measure quality of life through data. This demand has significantly spurred the development of wearable technology.”

The VeriSense platform integrates IMU (Inertial Measurement Unit) sensors and is compatible with any IMU-based application. The user operation is remarkably simple: users need only wear the sensor and place the VeriSense device within its signal range to enable automatic data upload. This capability is highly beneficial for monitoring complex musculoskeletal or neurological disorders, such as dystonia or epilepsy.

Unlike its previous products, VeriSense is the company’s first data platform directly linked to clinical trials. To maximize its utility in clinical trials, the VeriSense platform requires only five minutes of setup to initiate data collection, granting users access to raw clinical data rather than processed data, as is the case with Fitbit (a smartwatch capable of monitoring heart rate, sleep patterns, and other metrics).

“Shimmer sensors have been immensely helpful in my years of research,” said Dr. Paolo Bonato, Director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital and Associate Professor in the Department of Physical Medicine and Rehabilitation at Harvard Medical School. “The newly launched Verisense platform offers significant advantages: high-quality raw data, rapid and convenient system setup, secure and reliable data streaming, and an extended battery life of up to six months. These features have greatly enhanced the robustness of my clinical trial protocols.”

It is reported that starting in March, Shimmer will use Verisense in clinical trials related to Alzheimer’s disease, Parkinson’s disease, and cancer.

(Compiled by Feng Yutong)